$AXSM News

Axsome Therapeutics Resolves All Patent Litigation Related To Axsome's Product SUNOSI

Axsome's Auvelity: A New Treatment For Agitation In Alzheimer's Disease

Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $242

RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $302

Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $255

Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $260

Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $310

Baird Maintains Outperform on Axsome Therapeutics, Raises Price Target to $246

HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $290

Needham Maintains Buy on Axsome Therapeutics, Raises Price Target to $267

Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript

Axsome Therapeutics (NASDAQ:AXSM) Q1 Revenue Beat Misses Estimates as Launch Costs Surge

Axsome Therapeutics Q1 2026 Earnings Call: Complete Transcript

Axsome Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Strong Drug Sales Lift Axsome Revenue, But Profit Miss Drags Stock

HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $270

Axsome Therapeutics Q1 EPS $(1.26) Misses $(0.90) Estimate, Sales $191.203M Beat $189.193M Estimate

Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease Transcript

Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease - Slideshow